Saeedi Bejan J, Morison Doree Gardner, Kraft Colleen S, Dhere Tanvi
School of Medicine, the Departments of Medicine and Pathology and Laboratory Medicine, and the Division of Digestive Diseases, Emory University, Atlanta, Georgia.
Obstet Gynecol. 2017 Mar;129(3):507-509. doi: 10.1097/AOG.0000000000001911.
Clostridium difficile infection has been associated with negative outcomes in the general population and in pregnant patients. Fecal microbiota transplant has become the standard for treatment of recurrent as well as refractory C difficile infection.
We present a case of a 28-year-old pregnant woman who presented with recurrent C difficile infection despite treatment with vancomycin and fidaxomicin and underwent a successful fecal microbiota transplant through colonoscopy at 18 weeks of gestation. She no longer required antibiotics for the remainder of her pregnancy to treat C difficile and had a term vaginal delivery at 39 weeks of gestation.
Our pregnant patient tolerated and responded to a fecal microbiota transplant for treatment of recurrent C difficile infection. Future large-scale studies are needed to determine the efficacy, safety, and long-term effects of manipulating the microbiome in pregnant patients and the neonates.
艰难梭菌感染与普通人群及孕妇的不良结局相关。粪便微生物群移植已成为复发性及难治性艰难梭菌感染的治疗标准。
我们报告一例28岁孕妇，尽管接受了万古霉素和非达霉素治疗，仍出现复发性艰难梭菌感染，并在妊娠18周时通过结肠镜成功进行了粪便微生物群移植。在其剩余孕期中，她不再需要使用抗生素治疗艰难梭菌感染，并在妊娠39周时经阴道足月分娩。
我们的这位孕妇耐受了粪便微生物群移植，并对复发性艰难梭菌感染的治疗有反应。未来需要进行大规模研究，以确定在孕妇及新生儿中操纵微生物群的疗效、安全性及长期影响。
Zotero 插件